Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs

J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e360-e361. doi: 10.1111/jdv.16587. Epub 2020 Jun 8.

Abstract

Since December 2019, the pandemic coronavirus disease (2019‐nCoV; COVID‐19) has changed the approach to all dermatological diseases; in particular, psoriatic patients undergoing immunosuppressive drugs, such as biologics, can potentially show an increase risk of infection (1). However, few reports are available on the course of COVID‐19 infection in psoriatic patients treated with biological drugs (2). We describe a case series of four psoriatic patients treated with biologics who had a risk contact with COVID‐19.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Betacoronavirus
  • Biological Products / therapeutic use*
  • COVID-19
  • Coronavirus Infections / complications*
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / virology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / virology
  • Psoriasis / complications*
  • SARS-CoV-2

Substances

  • Biological Products